Terms: = Pancreatic cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
76 results:
1. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer.
Tushoski-Alemán GW; Herremans KM; Underwood PW; Akki A; Riner AN; Trevino JG; Han S; Hughes SJ
PLoS One; 2024; 19(2):e0297325. PubMed ID: 38346068
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract] [Full Text] [Related]
4. Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition.
Zhao M; Li L; Kiernan CH; Castro Eiro MD; Dammeijer F; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Aerts JG; Mueller YM; Katsikis PD
Sci Rep; 2023 Sep; 13(1):15678. PubMed ID: 37735204
[TBL] [Abstract] [Full Text] [Related]
5. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract] [Full Text] [Related]
6. Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.
Koh EK; Lee HR; Son WC; Park GY; Kim J; Bae JH; Park YS
Sci Rep; 2023 May; 13(1):7656. PubMed ID: 37169953
[TBL] [Abstract] [Full Text] [Related]
7. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
8. Simultaneous targeting of PD-1 and il-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
[TBL] [Abstract] [Full Text] [Related]
9. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract] [Full Text] [Related]
10. TGF-β2 antisense oligonucleotide enhances T-cell mediated anti-tumor activities by il-2 via attenuation of fibrotic reaction in a humanized mouse model of pancreatic ductal adenocarcinoma.
Lee HK; Nam MW; Go RE; Koo J; Kim TH; Park JE; Choi KC
Biomed Pharmacother; 2023 Mar; 159():114212. PubMed ID: 36610224
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
[TBL] [Abstract] [Full Text] [Related]
12. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.
Wang Y; Fang X; Li M; Ye J; Zhao S; Yu L; Wang J; Wang Y; Yan Z
Cancer Genet; 2022 Nov; 268-269():103-110. PubMed ID: 36288641
[TBL] [Abstract] [Full Text] [Related]
13. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract] [Full Text] [Related]
14. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
[TBL] [Abstract] [Full Text] [Related]
15. Targeting TNF-α for COVID-19: Recent Advanced and Controversies.
Guo Y; Hu K; Li Y; Lu C; Ling K; Cai C; Wang W; Ye D
Front Public Health; 2022; 10():833967. PubMed ID: 35223745
[TBL] [Abstract] [Full Text] [Related]
16. The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients.
Xing Y; Zhang X; Qin F; Yang J; Ai L; Wang Q; Zhai Y
Bioengineered; 2022 Feb; 13(2):2130-2138. PubMed ID: 35034581
[TBL] [Abstract] [Full Text] [Related]
17. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects.
Suarez-Carmona M; Williams A; Schreiber J; Hohmann N; Pruefer U; Krauss J; Jäger D; Frömming A; Beyer D; Eulberg D; Jungelius JU; Baumann M; Mangasarian A; Halama N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607895
[TBL] [Abstract] [Full Text] [Related]
18. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Luo X; Wang H; Ji D
Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
[TBL] [Abstract] [Full Text] [Related]
19. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vil-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Quixabeira DCA; Zafar S; Santos JM; Cervera-Carrascon V; Havunen R; Kudling TV; Basnet S; Anttila M; Kanerva A; Hemminki A
Front Immunol; 2021; 12():674400. PubMed ID: 34084172
[TBL] [Abstract] [Full Text] [Related]
20. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
[TBL] [Abstract] [Full Text] [Related]
[Next]
